These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 25454852)
1. Recommendations for strengthening NITAG policies in developed countries. Ricciardi GW; Toumi M; Poland G Vaccine; 2015 Jan; 33(1):1-2. PubMed ID: 25454852 [No Abstract] [Full Text] [Related]
2. Comparison of NITAG policies and working processes in selected developed countries. Ricciardi GW; Toumi M; Weil-Olivier C; Ruitenberg EJ; Dankó D; Duru G; Picazo J; Zöllner Y; Poland G; Drummond M Vaccine; 2015 Jan; 33(1):3-11. PubMed ID: 25258100 [TBL] [Abstract][Full Text] [Related]
3. Strategies for decision-making on vaccine use: the French experience. Loulergue P; Floret D; Launay O Expert Rev Vaccines; 2015 Jul; 14(7):917-22. PubMed ID: 25913015 [TBL] [Abstract][Full Text] [Related]
4. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country. Molina-Aguilera IB Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176 [No Abstract] [Full Text] [Related]
7. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes. Sosler S; Kallenberg J; Johnson HL Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172 [No Abstract] [Full Text] [Related]
8. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses. Andrus JK; Walker DG Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161 [No Abstract] [Full Text] [Related]
9. Introducing new vaccines into the South African national immunisation programme - a case study. Schoub BD; Mphahlele MJ; Ngcobo NJ; Hoosen AA; Meheus A Vaccine; 2012 Sep; 30 Suppl 3():C1-2. PubMed ID: 22939014 [No Abstract] [Full Text] [Related]
10. Evidence versus expert opinion in vaccination practice. Cook IF Hum Vaccin; 2010 May; 6(5):374-6. PubMed ID: 20484974 [No Abstract] [Full Text] [Related]
11. Vaccines without borders to Latin America. Avila-Aguero ML; Brea-del Castillo J; Falleiros-Arlant LH Expert Rev Vaccines; 2013 Nov; 12(11):1239-40. PubMed ID: 24117325 [No Abstract] [Full Text] [Related]
12. The imperative of vaccination. The Lancet Infectious Diseases Lancet Infect Dis; 2017 Nov; 17(11):1099. PubMed ID: 29115253 [No Abstract] [Full Text] [Related]
13. Introducing new vaccines in developing countries. Kochhar S; Rath B; Seeber LD; Rundblad G; Khamesipour A; Ali M; Expert Rev Vaccines; 2013 Dec; 12(12):1465-78. PubMed ID: 24195483 [TBL] [Abstract][Full Text] [Related]
14. Criteria for inclusion of vaccinations in public programmes. Houweling H; Verweij M; Ruitenberg EJ; Vaccine; 2010 Apr; 28(17):2924-31. PubMed ID: 20189486 [TBL] [Abstract][Full Text] [Related]
16. The role of health economic analyses in vaccine decision making. Black S Vaccine; 2013 Dec; 31(51):6046-9. PubMed ID: 23968768 [TBL] [Abstract][Full Text] [Related]
17. Strengthening vaccination policies in Latin America: an evidence-based approach. Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196 [TBL] [Abstract][Full Text] [Related]
19. New vaccines needed for pathogens infecting animals and humans: One Health. Gutiérrez AH; Spero DM; Gay C; Zimic M; De Groot AS Hum Vaccin Immunother; 2012 Jul; 8(7):971-8. PubMed ID: 22485046 [TBL] [Abstract][Full Text] [Related]
20. Q&A--Economic analyses for vaccine introduction decisions in low- and middle- income countries. Hutubessy R BMC Med; 2013 Mar; 11():71. PubMed ID: 23496946 [No Abstract] [Full Text] [Related] [Next] [New Search]